Document is current
Any future updates will be listed below
-
Authors
Ananya, Ananya
Holden, Kaitlyn G.
Gu, Zhiling
Nettleton, Dan
Mallapragada, Surya K.
Wannemuehler, Michael J.
Kohut, Marian L.
Narasimhan, Balaji
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
National Institutes of Health (R01 AI154458)
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 5 February 2023
First Online: 9 March 2023
Declarations
:
: All procedures involving animals were approved by the Institutional Animal Care and Use Committee at Iowa State University under protocol #IACUC-20-199.
: Not applicable.
: Balaji Narasimhan and Michael Wannemuehler are co-founders of ImmunoNanoMed Inc., a start-up with business interests in the development of nano-based vaccines against infectious diseases. Narasimhan also has a financial interest in Degimflex LLC. Surya Mallapragada is a co-founder of Degimflex LLC., a start-up with business interests in the development of flexible degradable electronic films for biomedical applications. She also has a financial interest in ImmunoNanoMed Inc.
